The interim guidelines for the prevention and treatment of Mpox in person with HIV infection issued by the United States CDC showed that JYNNEOS was well tolerated with similar immunogenicity in individuals with CD4 cell count of 200–750/μL, regardless of HIV infection status [13]. Here, CD4 is linked to HIV infectious disease.